The History and Development of HER2 Inhibitors
HER2 is highly expressed in a variety of malignant tumors and affects the prognosis of patients, making it a highly sensitive target for cancer therapy. Since the approval of the first HER2 inhibitor, trastuzumab, in 1998, HER2-targeted drugs have rapidly evolved. Currently, targeting HER2 drugs mai...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
MDPI AG,
2023-10-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_f653f1a47f8f43fdb70e499db3e8ba98 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Xiaohui Xia |e author |
| 700 | 1 | 0 | |a Chen Gong |e author |
| 700 | 1 | 0 | |a Yinan Zhang |e author |
| 700 | 1 | 0 | |a Huihua Xiong |e author |
| 245 | 0 | 0 | |a The History and Development of HER2 Inhibitors |
| 260 | |b MDPI AG, |c 2023-10-01T00:00:00Z. | ||
| 500 | |a 10.3390/ph16101450 | ||
| 500 | |a 1424-8247 | ||
| 520 | |a HER2 is highly expressed in a variety of malignant tumors and affects the prognosis of patients, making it a highly sensitive target for cancer therapy. Since the approval of the first HER2 inhibitor, trastuzumab, in 1998, HER2-targeted drugs have rapidly evolved. Currently, targeting HER2 drugs mainly include monoclonal antibodies (mAbs), tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs). This article reviews the development of HER2 inhibitors for various tumors over the past 20 years. | ||
| 546 | |a EN | ||
| 690 | |a HER2 inhibitors | ||
| 690 | |a cancer | ||
| 690 | |a antibodies | ||
| 690 | |a tyrosine kinase inhibitors | ||
| 690 | |a antibody-drug conjugates | ||
| 690 | |a Medicine | ||
| 690 | |a R | ||
| 690 | |a Pharmacy and materia medica | ||
| 690 | |a RS1-441 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Pharmaceuticals, Vol 16, Iss 10, p 1450 (2023) | |
| 787 | 0 | |n https://www.mdpi.com/1424-8247/16/10/1450 | |
| 787 | 0 | |n https://doaj.org/toc/1424-8247 | |
| 856 | 4 | 1 | |u https://doaj.org/article/f653f1a47f8f43fdb70e499db3e8ba98 |z Connect to this object online. |